Last edition
News about "John Tsai"
AstraZeneca and Daiichi Sankyo Partner with Summit on Datroway
AstraZeneca and Daiichi Sankyo enter clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumor types.
John Tsai | 05/10/2026 | By News Bureau
Daiichi Sankyo Begins Clinical Development of CD25-Targeted ADC DS1025
Daiichi Sankyo advances DS1025 into clinical development as a potential first-in-class CD25-targeted Antibody Drug Conjugate (ADC) for patients with advanced solid tumors.
John Tsai | 01/09/2026 | By News Bureau
EMA Committee Recommends Approval of AstraZeneca and Daiichi Sankyo's Enhertu Plus Pertuzumab
If approved, AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab would become first new treatment in the European Union (EU) in more than a decade for first-line HER2-positive metastatic breast cancer.
John Tsai | 25/07/2026 | By News Bureau | 108
Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer
Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.
John Tsai | 13/04/2026 | By News Bureau | 324
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy